A prospective study of the relationship between genital herpes and carcinoma of the uterine cervix. I. Seroepidemiology of herpes simplex virus type 1 and type 2 in women with a previous history of clinically diagnosed genital herpes.
The development of a simple, sensitive and reliable enzyme-linked immunosorbent assay (ELISA) for the exact titration of herpes simplex virus type 1 -- and type 2 -- specific antibodies in human serum has made it possible to perform large serological HSV type-specific diagnosis of clinical cases of post and present genital HSV infections. The distribution of HSV type-specific IgG antibody in 473 sera from women with a first episode of symptomatic genital herpes (group A), 602 sera from women with a previous history of symptomatic genital herpes (group B) and 945 sera from non-selected adult Danes (controls, group C) gave the following results: 34 percent of the women in group B had antibodies only to HSV type compared to 6 and 4 percent in group A and C respectively. 64 percent of women in group A were sero-negative, while only 9 and 18 percent sero-negative were found in group B and C respectively. A majority of the sero-negative in group A seroconverted. One third developed antibodies to HSV type 1 and two thirds to HSV type 2.
D000914:Antibodies, Viral / Q000032:analysis*; D005260:Female; D006558:Herpes Genitalis / Q000150:complications / Q000276:immunology*; D006801:Humans; D008297:Male; D011446:Prospective Studies; D018139:Simplexvirus / Q000276:immunology*; D002583:Uterine Cervical Neoplasms / Q000209:etiology*
D000914:Antibodies, Viral